Select Publications

Douillard JY et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: Docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: Final results of a randomised phase II study. Ann Oncol 2005;16(1):81-9. Abstract

Fossella F et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21(16):3016-24. Abstract

Fossella FV et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung
Cancer Study Group. J Clin Oncol 2000;18(12):2354-62. Abstract

Gandara DR et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group study (S9504). Clin Lung Cancer 2006;8(2):116-21. Abstract

Gandara DR et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504.
J Clin Oncol 2003;21(10):2004-10. Abstract

Hanna NH et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Proc ASCO 2007;Abstract 7512.

Heymach JV et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proc ASCO 2007a;Abstract 7544.

Heymach JV et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007b;25(27):4270-
7. Abstract

Heymach JV et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc ASCO 2006;Abstract 7016.

Kudoh S et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol 2006;24(22):3657-63. Abstract

Manegold C et al. Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC):
BO17704. Proc ASCO 2007;Abstract LBA7514.

Milleron B et al. IFCT0002 phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy with two different CT regimens in resectable non-small cell lung cancer (NSCLC): Early results. Proc ASCO 2007;Abstract 7519.

Natale RB et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Proc ASCO 2006;Abstract 7000.

Patel JD et al. Pemetrexed and carboplatin plus bevacizumab for advanced nonsquamous non-small cell lung cancer (NSCLC): Preliminary results. Proc ASCO 2007;Abstract 7601.

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Home

EDITOR
Neil Love, MD

INTERVIEWS
Paul A Bunn Jr, MD
- Select publications

Nasser H Hanna, MD
- Select publications

Antoinette J Wozniak, MD
- Select publications

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office